Introduction
============

During ontogeny the hypothalamic-pituitary-adrenal (HPA) axis undergoes a period of quiescence (Levine et al., [@B29]; Schapiro et al., [@B52]). This so-called stress hypo-responsive period (SHRP), which in the mouse lasts from about postnatal day 1 to postnatal day 12 (Schmidt et al., [@B55]), is characterized by low basal corticosterone levels and a decreased responsiveness to a variety of stressors (Cirulli et al., [@B12]; Rosenfeld et al., [@B47]; Schmidt et al., [@B54]).

Although suppressed in response, the stress system of the neonate is still capable to respond to more severe and possibly life threatening challenges, as e.g. exposure to cold or ether fumes (Schoenfeld et al., [@B62]; Walker and Dallman, [@B72]; Walker et al., [@B73]). A profound activation of the HPA axis occurs following prolonged separation of maternal signals, which not only increases basal corticosterone levels, but also enhances the responsiveness of the stress system to mild challenges (Levine, [@B28]; Schmidt et al., [@B59]).

Disruption of the SHRP, which has also been postulated to exist to some extent in humans (Gunnar, [@B20]; Gunnar and Donzella, [@B21]), has been shown to result in numerous long-lasting behavioral and neuroendocrine consequences in both humans and animals (Bernet and Stein, [@B7]; Heim et al., [@B23], [@B24]; Plotsky et al., [@B44]; Weaver et al., [@B74]). While most of the earlier work was performed in rats, many recent studies studied early life stress paradigms using mice (Cruz et al., [@B13]; Kawakami et al., [@B26]; Macri and Laviola, [@B30]; Marco et al., [@B31]; Ognibene et al., [@B37]; Rice et al., [@B46]). However, due to the wide variability of postnatal manipulations, species and strain differences, the data on the long-term effects of early life stress are often inconsistent. For instance, while many authors have shown an increased anxiety after postnatal stress (Veenema et al., [@B70]), other reports show no clear phenotype (Millstein and Holmes, [@B34]) or even a decreased anxiety (Fabricius et al., [@B17]). One of the main problems in understanding these different outcomes is the lack of knowledge about the acute effects of the different postnatal stress paradigms.

The mechanism of HPA axis regulation during the SHRP is intriguing, as it may explain possible regulatory pathways in the adult animals. We could recently show that an apparently enhanced glucocorticoid receptor-mediated feedback plays an essential role in maintaining low stress responsiveness in the neonate (Schmidt et al., [@B60], [@B61]). Metabolic signals, which are altered due to maternal separation, activate the arcuate nucleus and seem to overcome this GR blockade via an CRH-mediated central pathway (Schmidt et al., [@B57],[@B58]). In addition, maternal signals as licking and grooming have been identified as essential parameters to ensure low HPA-system activity (Suchecki et al., [@B66]; van Oers et al., [@B69]).

Most of the current knowledge about the HPA axis regulation in the neonate is thus based on hypothesis-driven approaches. However, additional, so far uninvestigated brain systems are likely to contribute to the acute and long-term effects of maternal separation and early trauma. In the current study we therefore addressed this question by performing a microarray-based gene expression analysis of maternally separated and non-separated mouse pups. We selected the paraventricular nucleus (PVN) as a main region of interest, as most of the acute gene expression changes due to maternal separation have so far been reported for this brain structure. Based on a gene expression profiling approach we are able to identify and functionally validate the brain renin-angiotensin system as a modulator of stress system function during the SHRP.

Materials and Methods
=====================

Animals
-------

The offspring of 3-month-old C57Bl6/N mice (obtained from Charles River) was used in this study. After a habituation period of 1 week, two females were mated with one male in standard mouse polycarbonate cages (45 × 25 × 20 cm) containing sawdust bedding. Pregnant females were single housed and transferred to clean polycarbonate cages containing sawdust and two sheets of paper towels for nest material during the last week of gestation. Pregnant females were checked for litters daily between 9 and 10 a.m. If litters were found, the day of birth was defined as day 0 for that litter. On the day after parturition, day 1, each litter was culled to eight healthy pups (four males and four females) and remained undisturbed until used in the experiment. All animals were housed under a 12L:12D cycle (lights on at 6 a.m.) and constant temperature (23 ± 2°C) and humidity (55 ± 5%) conditions. Food and water was provided *ad libitum*.

The experiments were carried out in accordance with European Communities Council Directive 86/609/EEC. All efforts were made to minimize animal suffering during the experiments. The protocols were approved by the committee for the Care and Use of Laboratory Animals of the Government of Upper Bavaria, Germany.

Experimental design
-------------------

### Experiment 1: gene expression profile

A total of 6 litters were used in the study. Litters were randomly assigned to either a maternally non-separated or 24-h maternally separated condition. All pups from a litter were sacrificed by decapitation and trunk blood was collected immediately after the 24-h deprivation period or -- in the case of the control litters -- immediately after separation from the mother on postnatal day 9.

### Experiment 2: functional validation

A total of 8 litters were used in the study. Each nest was assigned randomly to one of the two conditions, 8-h maternal separation or non-separated control. Pups in each litter were either treated subcutaneously with vehicle (saline) or 1 mg/kg of the angiotensin type I receptor AT(1) antagonist candesartan (provided by AstraZeneca, Wedel, Germany) 2 h after the onset of separation (6 h before testing). The dosage of the drug was based on literature reports (Armando et al., [@B3]; Fan et al., [@B18]) and it has been demonstrated that candesartan crosses the blood-brain barrier (Pavel et al., [@B40]). The injection volume was 30 μl. At the time of testing, all pups from a litter were sacrificed by decapitation.

Maternal separation
-------------------

Maternal separation took place in a separate room in the animal facility under similar light and temperature conditions as mentioned previously. The initiation day of maternal separation for all experiments was postnatal day 8. If a nest was assigned to maternal separation, mothers were removed from their home cages between 8 and 10 a.m. The home cage, containing the litter, was then placed on a heating pad maintained at 30--33°C. Neither food nor water was available during the separation period. In experiment 1, separation lasted for 24 h. In experiment 2, pups were only separated for 8 h, in order to assess the role of the brain renin-angiotensin system in activating the HPA axis. The 8-h time-point was chosen based on earlier studies, which indicated a full activation of the HPA axis during the first 8 h of separation (Schmidt et al., [@B59]).

Sampling procedure
------------------

Trunk blood from all pups was collected individually in labeled 1.5 ml EDTA-coated microcentrifuge tubes. All blood samples were kept on ice and later centrifuged for 15 min at 6000 rpm at 4°C. Plasma was transferred to clean, labeled 1.5 ml microcentrifuge tubes. All plasma samples were stored frozen at −20°C until the determination of corticosterone (experiments 1 and 2) and ACTH (experiment 2). ACTH and corticosterone were measured by RIA (MP Biomedicals Inc.; sensitivity 10 pg/ml and 6.25 ng/ml, respectively). Whole heads (without skin and jaw) were removed, frozen in isopropane and stored at −80°C for microarray analysis or *in-situ* hybridization.

Microarray procedure
--------------------

The brains of six animals per group were used. Frozen brains were sectioned at −20°C in a cryostat microtome at 100 μm in the coronal plane through the level of the hypothalamic PVN. The sections were mounted on superfrost plus slides (Menzel, Braunschweig, Germany) and tissue micropunches were taken using a sample corer of 1 mm diameter (Fine Science Tools, Heidelberg, Germany). The PVNs of two animals from the same group were pooled into one sample, giving a total of three samples for each treatment. Punches were immediately transferred to frozen 1.5 ml plastic tubes and stored ad −80°C until RNA isolation. The accuracy of the punch was controlled by cresyl violet counterstaining of the punched sections and confirming the punch location under a light microscope.

Total RNA of the punched tissue was isolated with the Trizol (Invitrogen GmbH, Karlsruhe, Germany) method following the manufacturers' protocol. Isolated RNA was then amplified in one round using the Ambion Amino Allyl MessageAmp aRNA kit (Ambion, Huntingdon, UK). RNA samples were quantified by spectrophotometry and RNA integrity checked on 1% agarose gels using a deionized formamide-based loading buffer. Equal amounts of total aRNA were pooled to one "non-separated" and one "separated" sample containing 40 μg of aRNA each and dye coupled using indirect labeling. To exclude dye bias, one-half of each sample was coupled to cyanine 3 (Cy3) and the other one-half to cyanine 5 (Cy5). The pooled samples were hybridized on five Max-Planck Institute 24 k mouse cDNA arrays (Max-Planck Institute of Psychiatry, Munich, Germany) for each dye coupling combination (10 arrays total) and scanned on a PerkinElmer Life Sciences (Rodgau-Jügesheim, Germany) ScanArray 4000 laser scanner as described previously (Deussing et al., [@B14]).

*In-situ* hybridization
-----------------------

The brains of eight animals per group were used for *in-situ* hybridization (different animals than used for microarray analysis). Frozen brains were sectioned at −20°C in a cryostat microtome at 16 μm in the coronal plane through the level of the hypothalamic PVN. The sections were thaw-mounted on superfrost plus slides (Menzel, Braunschweig, Germany), dried and kept at −80°C. *In-situ* hybridization using ^35^S UTP labeled ribonucleotide probes were performed as described previously (Schmidt et al., [@B53]). For angiotensinogen, riboprobe synthesis was carried out from a mouse brain cDNA library, yielding a 711 bp long probe (nucleotides GGATACAC + 703 of accession no NM007428). The riboprobes for corticotropin releasing hormone (CRH) and the glucocorticoid receptor (GR) were described previously (Schmidt et al., [@B56]). The slides were apposed to Kodak Biomax MR film (Eastman Kodak Co., Rochester, NY, USA) and developed. Autoradiographs were digitized, and relative expression was determined by computer-assisted optical densitometry (Scion Image, Scion Corporation). The mean of four measurements was calculated from each animal.

Data analysis
-------------

The microarray data were quantified using the fixed circle quantification method of QuantArray (PerkinElmer Life Sciences) and a nonlinear regression method (Yang et al., [@B76]) implemented in the statistical software R[1](#fn1){ref-type="fn"}. To correct for multiple testing, *p*-values were adjusted following the false discovery rate (FDR) method (Benjamini and Hochberg, [@B6]). An adjusted *p*-value of \<0.05 was considered statistically significant. Differentially expressed genes were imported into the BiblioSphere software V 7.20 (Genomatix, Munich, Germany) and assigned to Gene Ontology categories to identify their biological function.

For the *in-situ* hybridization and endocrine data, the results were analyzed by analysis of variance procedures (ANOVA) with the level of significance set at *p* \< 0.05. The initial analysis included sex as a factor; once it was determined that sex was not a significant factor, the data were collapsed across this variable. Where appropriate, tests of simple main and interaction effects were made with the Mann--Whitney--*U* test. Data are presented as mean ± SEM.

Results
=======

Experiment 1: gene expression profile
-------------------------------------

### Endocrine validation

To validate the success of the maternal deprivation procedure, plasma corticosterone was measured. As expected, maternal separation resulted in a significant increase of circulating corticosterone (non-separated: 6.65 ± 1.64 ng/ml; separated: 109.01 ± 7.95 ng/ml; *p* \< 0.05).

### Microarray results

The data discussed in this publication have been deposited in NCBIs Gene Expression Omnibus (GEO)[2](#fn2){ref-type="fn"} and are accessible through GEO Series accession number GSE14687. For the microarray analysis only genes with a fold-regulation of 1.5 or higher and an adjusted *p*-value of less than 0.05 were regarded as differentially regulated. Using these cut-off criteria, we identified 52 differentially expressed genes. Of these genes, 37 were up-regulated in the maternally separated group (see Table [1](#T1){ref-type="table"}), while 15 genes were down-regulated (see Table [2](#T2){ref-type="table"}). Maternal separation affected the expression of genes involved in various different functions, including apoptosis, metabolic processes, signal transduction, cell-cell interaction, gene expression, development, cellular transport or proliferation. For the current study, we chose to focus on the involvement of the angiotensinogen gene (AGT) in maternal separation for further validation and follow-up studies. The up-regulation of AGT in separated animals suggested a functional role of the brain renin-angiotensin system (RAS) in regulating the response to maternal separation. This system has previously been indicated to be involved in stress system regulation and dysregulation in adulthood (Armando et al., [@B2], [@B3]; Plotsky et al., [@B43]; Raasch et al., [@B45]). In addition, genetic variation in genes involved in the brain RAS have been linked to disorders as unipolar depression or panic disorder (Baghai et al., [@B4]; Olsson et al., [@B39]). However, few data on the involvement of the brain RAS in regulating the HPA axis during ontogeny are available.

###### 

**List of significantly up-regulated genes in the PVN region of the hypothalamus in 9-day-old maternally separated mouse pups compared to controls**.

  Gene symbol     Gene name                                                 Function               Accession number   Fold regulation   *p*-Value
  --------------- --------------------------------------------------------- ---------------------- ------------------ ----------------- -----------
  Rap2ip          Rap2 interacting protein                                  Signal transduction    AI839996           2.6876            0.0048
  BC055107        BC055107                                                  Unknown                AI836637           2.4745            0.0027
  Gjb6            Gap junction membrane channel protein beta 6              Development            AI847389           2.3288            0.0027
  DAP-3           Disks large-associated protein 3                          Cell-cell signalling   AI850878           2.2489            0.0267
  NA              NA                                                        Unknown                AI854246           2.1465            0.0019
  2610304G08Rik   RIKEN cDNA 2610304G08 gene                                Unknown                AI843346           2.0788            0.0073
  Ttf2            Transcription termination factor, RNA polymerase II       Gene expression        AA473992           2.0507            0.0197
  Paqr8           Progestin and adipoQ receptor family member VIII          Unknown                AI843077           1.9711            0.0224
  Agt             Angiotensinogen                                           Signal transduction    AI838902           1.934             0.028
  Hipk3           Homeodomain interacting protein kinase 3                  Apoptosis              AI449703           1.9338            0.0338
  Atp1a2          ATPase, Na+/K+ transporting, alpha 2 polypeptide          Cell-cell signalling   AI851097           1.8715            0.0278
  Glul            Glutamate-ammonia ligase (glutamine synthase)             Metabolic processes    AI835674           1.8393            0.0003
  Sqrdl           Sulfide quinone reductase-like (yeast)                    Metabolic processes    AA473822           1.8204            0.0201
  Olah            Oleoyl-ACP hydrolase                                      Metabolic processes    AI414810           1.775             0.0246
  Cln8            Ceroid-lipofuscinosis, neuronal 8                         Apoptosis              AI843820           1.7421            0.036
  Ipw             Imprinted gene in the Prader-Willi syndrome region        Unknown                AI852618           1.7417            0.0355
  Purb            Purine rich element binding protein B                     Apoptosis              AI854464           1.7187            0.0005
  NA              Transcribed sequence                                      Unknown                AI413315           1.71              0.0012
  Aldo3           Aldolase 3, C isoform                                     Metabolic processes    AI841101           1.7039            0.0044
  Ddx3y           DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked        Transcription          AI448347           1.698             0.0135
  Mapre2          Microtubule-associated protein, RP/EB family, member 2    Cellular structure     AI227140           1.6343            0.0022
  1110018M03Rik   RIKEN cDNA 1110018M03 gene                                Unknown                AI854593           1.6336            0.0475
  Sparc           Secreted acidic cysteine rich glycoprotein                Signal transduction    AI840232           1.6115            0.0081
  2210013O21Rik   RIKEN cDNA 2210013021 gene                                Unknown                AI846437           1.5878            0.0182
  Slc24a2         Solute carrier family 24, member 2                        Transport              AI847460           1.5781            0.0355
  Scn2b           Sodium channel, voltage-gated, type II, beta              Transport              AI840361           1.5585            0.0035
  Map4k4          Mitogen-activated protein kinase kinase kinase kinase 4   Signal transduction    AI465256           1.5571            0.0427
  I125            Interleukin 25                                            Signal transduction    W71193             1.5411            0.0083
  Cfdp            Craniofacial development protein 1                        Apoptosis              AI225952           1.54              0.0062
  Xpa             Xeroderma pigmentosum, complementation group A            Apoptosis              AI838722           1.5375            0.0101
  Mt1             Metallothionein 1                                         Signal transduction    AI427514           1.525             0.012
  0610007C21Rik   RIKEN cDNA 0610007C21 gene                                Unknown                AI837774           1.5166            0.0221
  Tmeml30         Transmembrane protein 130                                 Unknown                AI854455           1.5158            0.0041
  Gas5            Growth arrest specific 5                                  Apoptosis              AI848205           1.5123            0.0044
  Gtl2            GTL2, imprinted maternally expressed untranslated mRNA    Proliferation          AI847231           1.5118            0.0022
  Clstn3          Calsyntenin 3                                             Cell-cell signalling   AI851951           1.5075            0.0355
  Lmna            Lamin A                                                   Cellular structure     AI845319           1.5062            0.0224

###### 

**List of significantly down-regulated genes in the PVN region of the hypothalamus in 9-day-old maternally separated mouse pups compared to controls**.

  Gene symbol     Gene name                                                      Function               Accession number   Fold regulation   *p*-Value
  --------------- -------------------------------------------------------------- ---------------------- ------------------ ----------------- -----------
  Xist            Inactive X specific transcripts                                Gene expression        AI227127           −2.1304           0.0062
  Dcpp            Demilune cell and parotid protein                              Development            AA036082           −2.1191           0.0345
  NA              13 days embryo heart cDNA                                      Unknown                AA259358           −1.7566           0.0313
  St8sia4         ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4   Metabolic processes    AI385627           −1.6858           0.0355
  Hmgcs1          3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1               Metabolic processes    AI841574           −1.6697           0.0009
  Sfrs11          Splicing factor, arginine/serine-rich 11                       Apoptosis              AI465457           −1.6512           0.0056
  Syt4            Synaptotagmin 4                                                Cell-cell signalling   AI843967           −1.6253           0.0201
  NA              Transcribed sequences                                          Unknown                AI839136           −1.6099           0.0452
  NA              7 days neonate cerebellum cDNA, clone:A730008E19               Unknown                W78304             −1.5498           0.0292
  Slurp1          Secreted Ly6/Plaur domain containing 1                         Metabolic processes    AI415082           −1.5308           0.0278
  Rtn3            Reticulon 3                                                    Apoptosis              AI852459           −1.5302           0.013
  Mtap1b          Microtubule-associated protein 1 B                             Development            AI852731           −1.5183           0.0104
  Tcf712          Transcription factor 7-like 2, T-cell specific, HMG-box        Gene expression        AI451561           −1.516            0.0131
  B230208H17Rik   RIKEN cDNA B230208H17 gene                                     Unknown                AI835464           −1.5151           0.0337
  Zfp535          Zinc finger protein 535                                        Unknown                AA272875           −1.5089           0.0421

### Validation by in-situ hybridization

*In-situ* hybridization was used to independently verify the results from the previous microarray analysis as well as to determine brain expression and distribution of the regulated gene. The results are shown in Figure [1](#F1){ref-type="fig"}. Under basal condition, we observed a weak expression of AGT in hypothalamic and thalamic nuclei, with little or no expression in cortical or limbic brain structures (Figure [1](#F1){ref-type="fig"}D). Following maternal separation angiotensinogen expression was significantly up-regulated in the hypothalamus (MWU: *p* \< 0.01). In addition, an up-regulation of this gene could also be demonstrated in the ventral thalamic nucleus (MWU: *p* \< 0.01). No significant regulation of AGT was found in the cortex (MWU: *p* \< 0.421).

![**Validation of expression changes of angiotensinogen by *in-situ* hybridization**. A significant up-regulation of angiotensinogen was found in the PVN **(A)** and the ventral thalamic nucleus **(B)**. No significant expression differences were observed in the cortex **(C)**. Figure **(D)** shows representative autoradiograph pictures of angiotensinogen mRNA expression in maternally non-separated (NSEP) and maternally separated (SEP) animals. Left arrow: ventral thalamic nucleus; right arrow: paraventricular nucleus. \*Significant from NSEP, *n* = 6 per group.](fnmol-02-001-g001){#F1}

Experiment 2: functional validation
-----------------------------------

In order to address a possible functional consequence of the differential regulation of AGT, the role of the brain renin-angiotensin system (RAS) in modulating maternal separation was addressed. For this experiment we chose to separate the animals for a shorter time period, to examine the involvement of the brain RAS in the activation of the HPA axis due to maternal separation. In previous studies we could show, that the activation of the stress system occurs during the first 8 h of maternal separation (Schmidt et al., [@B59]). Two hours after the onset of the separation period, animals received an injection of either the AT(1) receptor antagonist candesartan or vehicle (saline). For corticosterone, ANOVA revealed a significant effect of condition \[*F*(1,60) = 347.077 (*p* \< 0.0001)\], but not for treatment \[*F*(1,60) = 0.499 (*p* \< 0.5)\]. Maternal separation resulted in a robust increase in corticosterone secretion (Figure [2](#F2){ref-type="fig"}A). This effect was not different between the two treatment groups. For ACTH, ANOVA revealed a main effect of condition \[*F*(1,60) = 89.59 (*p* \< 0.0001)\] and treatment \[*F*(1,60) = 54.018 (*p* \< 0.0001)\], as well as an interaction of condition and treatment \[*F*(1,60) = 32.406 (*p* \< 0.0001)\]. Maternal separation increased ACTH plasma levels compared to non-separated controls. This increase was significantly higher in candesartan-treated pups compared to vehicle-treated deprived pups (Figure [2](#F2){ref-type="fig"}B).

![**Effects of candesartan treatment in non-separated (NSEP) and separated (SEP) mouse pups on corticosterone (A) and ACTH (B) plasma values**. Maternal separation increased corticosterone and ACTH secretion. No effects of candesartan treatment were seen for corticosterone. For ACTH, candesartan treatment resulted in a significant increase of ACTH secretion compared to vehicle-treated pups of the same condition. \*Significant from NSEP, \#significant from vehicle treatment, *n* = 16 per group.](fnmol-02-001-g002){#F2}

For the CRH mRNA expression in the PVN, ANOVA revealed a main effect of condition \[*F*(1,27) = 14.15 (*p* \< 0.001)\] and treatment \[*F*(1,27) = 23.404 (*p* \< 0.0001)\]. Maternal separation resulted in a decrease of CRH mRNA expression in the PVN in vehicle-treated animals (Figures [3](#F3){ref-type="fig"}A and B). This effect was mimicked by candesartan treatment in non-separated pups, resulting in significantly lower CRH mRNA expression levels compared to vehicle controls. The lowest CRH mRNA expression was observed in maternally separated animals, which received a candesartan treatment 6 h before testing.

![**Effects of candesartan treatment in non-separated (NSEP) and separated (SEP) mouse pups on CRH mRNA expression (A) in the PVN and GR mRNA expression (C) in the CA1 region of the hippocampus**. CRH mRNA expression was significantly decreased by maternal separation and candesartan treatment. The lowest expression of CRH was observed in candesartan-treated, separated mouse pups. GR expression was not affected by maternal separation or candesartan treatment. However, when combined we observed a significant down-regulation of GR mRNA expression. **(B)** and **(D)**: Representative autoradiograms of CRH mRNA expression in the PVN and GR mRNA expression in the hippocampus, respectively. \*Significant from NSEP, \#significant from vehicle treatment, *n* = 8 per group.](fnmol-02-001-g003){#F3}

GR mRNA expression was measured in the CA1 area of the hippocampus. ANOVA revealed a main effect of treatment \[*F*(1,27) = 11.75 (*p* \< 0.01)\], as well as an interaction of condition and treatment \[*F*(1,27) = 9.951 (*p* \< 0.01)\]. In vehicle-treated animals, GR mRNA expression was not altered by 8 h of maternal separation. Candesartan treatment of non-separated pups did also not alter GR mRNA expression. However, maternally separated pups, which were treated with candesartan, showed a significantly decreased GR mRNA expression compared to saline treated, separated pups as well as compared to non-separated, candesartan-treated pups (Figures [3](#F3){ref-type="fig"}C and D).

Discussion
==========

Early trauma has been shown to result in lasting consequences and an increased risk for a number of diseases, including psychiatric disorders (Chapman et al., [@B11]; Dong et al., [@B15]; Heim et al., [@B22]). The mechanism by which trauma affects health is so far not understood completely.

To study the underlying molecular mechanisms that lead to disease, animal models as maternal separation have been used to model early traumatic events. Numerous groups have shown that the paradigm of maternal separation results in long-lasting neuroendocrine and behavioral consequences, thereby mimicking the human situation of early trauma (Ladd et al., [@B27]; Macri and Laviola, [@B30]; Oitzl et al., [@B38]; Rots et al., [@B48]; Suchecki et al., [@B65]; Sutanto et al., [@B68]; Workel et al., [@B75]). In the current study, we examined gene expression changes which occur as a direct consequence of a single 24-h maternal separation period in order to identify signal cascades and brain systems that are regulated by maternal separation. This specific paradigm was chosen as the single separation episode is clearly defined in time and issues of adaptation to the separation can be avoided (Enthoven et al., [@B16]). We focused on the area of the hypothalamic PVN, as this brain region plays a key role in regulating HPA axis activity. Our unbiased, microarray-based approach resulted in the identification of 52 differentially regulated genes. The majority of the regulated genes were found to be up-regulated (37), while only 15 genes were down-regulated as a consequence of maternal separation.

One of the highest regulated genes was the angiotensinogen gene, which we independently validated by *in-situ* hybridization. Angiotensinogen is the precursor of angiotensin I that in turn is transformed into angiotensin II which is the primary effector of the brain renin-angiotensin system (RAS). First postulated in 1971 (Ganten et al., [@B19]), the main functions of the brain RAS are regulation of fluid electrolyte homeostasis and modulation of cardiovascular responses (Johnson and Thunhorst, [@B25]; Phillips and Sumners, [@B42]). However, this brain system has also been implicated in the regulation of memory, cognition, addiction as well as stress system regulation and has been associated with mood disorders (Belcheva et al., [@B5]; Saab et al., [@B49]; Saavedra et al., [@B50]). We therefore chose to further investigate, whether the activation of angiotensinogen after maternal separation might be of a functional consequence for the function of the stress system in the neonate. For the pharmacological validation of the involvement of angiotensinogen in modulating HPA axis activity we focused on the first 8 h of the separation period, as we have previously shown that activation occurs during this time (Schmidt et al., [@B59]).

We found robust changes in ACTH release following application of the AT(1) receptor antagonist candesartan in maternally separated animals. This change in ACTH release was not reflected in the corticosterone secretion at that time point. There are various possible explanations for this phenomenon. Numerous reports indicate that activation of AT(1) receptors increases corticosterone release from the adrenal cortex (Aguilar et al., [@B1]; Nithipatikom et al., [@B35]). This mechanism might also be involved in increasing adrenal sensitivity and adrenal corticosterone secretion during maternal separation. Alternatively this effect might be due to a contributing impact of the AT(2) receptor. Blockade of the AT(1) receptor results in increased circulating angiotensin II (Campbell, [@B9]), which is in turn stimulating the AT(2) receptor (Siragy and Carey, [@B64]). Blockade of AT(1) receptors with candesartan might thus on one hand activate the central part of the HPA axis, but block corticosterone release at the adrenal level. Alternatively, high ACTH levels at the time of testing could result in a higher corticosterone secretion at later time points.

In the brain, candesartan treatment in non-separated mouse pups mimicked the effects of maternal separation. CRH mRNA expression was equally decreased after maternal separation and candesartan treatment. This finding is intriguing, as the decrease of CRH expression following maternal separation remains a puzzling phenomenon. Our data indicate that the brain RAS might be directly involved in regulation of CRH mRNA expression in the neonate, independent of peripheral corticosterone concentrations. These data are in line with reports in adult animals, where angiotensin II was found to increase CRH mRNA expression in the PVN, an area where predominantly the AT(1) receptor is expressed (Sumitomo et al., [@B67]). Further, a blockade of AT(1) receptors seemed to exponentiate the central effects of maternal separation. The lowest expression levels of CRH mRNA in the PVN were found in candesartan-treated, maternally separated animals. In this group we also detected a decrease in GR mRNA in the hippocampus, a process that normally occurs only at longer separation periods (Schmidt et al., [@B59]). These data are in contrast to the adult situation, where the brain RAS has mostly been found to activate the stress system (Saavedra and Benicky, [@B51]), suggesting a different role of the brain RAS in the developing brain. This hypothesis is further supported by the different AT(1) receptor distribution during development and adulthood (Millan et al., [@B33]; Nuyt et al., [@B36]; Shanmugam et al., [@B63]).

Angiotensinogen is a precursor protein for a number of different cleavage products that act on at least four different angiotensin receptors in the brain (Phillips and de Oliveira, [@B41]). While in the current manuscript we observed a clear effect by blocking the AT(1) receptor, an additional involvement of the AT(2) or AT(4) receptors can not be excluded. Both receptors are expressed in the PVN (von Bohlen und Halbach and Albrecht, [@B71]). While treatment with an angiotensin converting enzyme (ACE) inhibitor should have similar effects compared to candesartan treatment, additional studies using specific AT(2) or AT(4) antagonists are needed to unravel the role of these receptors in the effects of maternal deprivation.

As different postnatal stress paradigms, including 24-h maternal separation, have long-lasting physiological and behavioral consequences, it is intriguing to speculate which role the brain RAS might play in these effects. On one hand, early life stress effects could lastingly affect the function of the brain RAS, thereby influencing the development or the adult reactivity of the stress system. On the other hand, the lasting effects of early life stress could be dependent on specific genetic risk alleles, similar to e.g. the serotonin transporter or the CRH receptor type 1 (Bradley et al., [@B8]; Caspi et al., [@B10]). However, while polymorphisms in the brain RAS have been linked to depression and bipolar disorder (Meira-Lima et al., [@B32]; Saab et al., [@B49]), we are not aware of any study investigating the interaction of these polymorphisms with e.g. childhood trauma.

In summary, our data indicate that during postnatal development the brain RAS functions to suppress HPA axis activity. Blockade of this system results in a central (but not peripheral) activation of the HPA axis under basal conditions and enhances the response to maternal separation. Thus, the up-regulation of angiotensinogen after maternal separation functions to suppress the separation-induced activation of the stress system.
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